Markets:

Overview

News

Currencies

International

Treasuries

Cel-Sci Corporation Common Stock (NY:CVM)

5.800 -0.070 (-1.19%)

Streaming Delayed Price Updated: 10:26 AM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cel-Sci Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

March 14, 2025

From CEL-SCI Corporation

Via Business Wire

Stay updated with the stocks that are on the move in today's pre-market session. ↗

February 20, 2025

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

February 20, 2025

From CEL-SCI Corporation

Via Business Wire

CVM Stock Earnings: CEL-SCI Misses EPS for Q3 2024 ↗

August 16, 2024

CVM stock results show that CEL-SCI missed analyst estimates for earnings per share the third quarter of 2024.

Via InvestorPlace

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

February 18, 2025

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

January 14, 2025

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Announces Closing of $5 Million Offering

December 31, 2024

From CEL-SCI Corporation

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 30, 2024

Via Benzinga

Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November ↗

December 30, 2024

Via Benzinga

Crude Oil Gains 1%; Chicago PMI Falls In December ↗

December 30, 2024

Via Benzinga

US Stocks Open Lower; Dow Tumbles 600 Points ↗

December 30, 2024

Via Benzinga

Topics Stocks

What's Going On With Cel-Sci Shares Premarket On Monday? ↗

December 30, 2024

Cel-Sci announces public offering of 16.13M shares at $0.31 per share, aiming to raise $5M for Multikine development and general purposes.

Via Benzinga

US Stock Futures Slip After Friday's Fall: 'Santa Rally' In Doubt? Analyst Calls It A Bit Of Profit-Taking ↗

December 30, 2024

U.S. stock futures declined on Monday after ending lower on Friday. All four index futures slipped in trade.

Via Benzinga

Why Vincerx Pharma Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket ↗

December 30, 2024

Via Benzinga

CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday ↗

December 30, 2024

Via Benzinga

CEL-SCI Announces Pricing of $5 Million Public Offering

December 29, 2024

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Announces Proposed Public Offering of Common Stock

December 27, 2024

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

December 12, 2024

From CEL-SCI Corporation

Via Business Wire

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

November 07, 2024

From CEL-SCI Corporation

Via Business Wire

FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

October 22, 2024

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

October 01, 2024

From CEL-SCI Corporation

Via Business Wire

CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

September 16, 2024

From CEL-SCI Corporation

Via Business Wire

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

September 10, 2024

From CEL-SCI Corporation

Via Business Wire

The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

September 04, 2024

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

August 15, 2024

From CEL-SCI Corporation

Via Business Wire

BioMedNewsBreaks — CEL-SCI Corp. (NYSE American: CVM) Closes on $10.8M Best-Efforts Offering

August 02, 2024

Via Investor Brand Network

CEL-SCI Announces Closing of $10.8 Million Offering

July 29, 2024

From CEL-SCI Corporation

Via Business Wire

Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

July 26, 2024

Via Benzinga

CEL-SCI Announces Pricing of $10.8 Million Offering

July 26, 2024

From CEL-SCI Corporation

Via Business Wire

CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

July 26, 2024

From CEL-SCI Corporation

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.